PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Palbociclib (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Goserelin; Letrozole; Pertuzumab; Tamoxifen; Trastuzumab
Indications Advanced breast cancer; Carcinoma
Focus Pharmacodynamics
Acronyms PETREMAC

01 Sep 2022 Pooled analysis assessing HRD data detected by panel sequencing obtained as part of routine clinical care published in the Clinical Cancer Research
23 Nov 2020 Protocol was amended mandating more potent chemotherapy regimens without PARP inhibition after the initial 10 weeks of olaparib monotherapy phase.
23 Nov 2020 Results (n=32) assessing effectiveness of PARP inhibitors receiving initial olaparib monotherapy in treatment arms G/H published in the Annals of Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com